Abstract
Epigenetic modifications are dynamic and heritable and occur independently of DNA sequence. Aberrant epigenetic alterations can lead to inappropriate gene expression and promote tumorigenesis. The knowledge that these epigenetic alterations are reversible has opened up new targeted therapeutic strategies for cancer treatment. CRISPR/dCas9 is a promising technology for precision cancer therapy. Once coupled to epigenetic effectors, CRISPR/dCas9 can function as an epigenetic editing tool displaying strong specificity and high efficiency. This review describes different CRISPR systems developed in the recent years for targeted alteration of epigenetic markers, such as DNA methylation or histone modification, and their potential as therapeutic agent and research tools for basic understanding of cancer epigenetics.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
